Macrostat (Shanghai) Clinical Research
Macrostat (Shanghai) Clinical Research is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
I4V-MC-JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I4V-MC-JAHW: An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
I5Q-MC-CGAT:A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I5Q-MC-CGAS: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I4V-MC-JAHU: Open-Label, Randomized Study with a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children from 1 to Less Than 18 Years of Age with Systemic Juvenile Idiopathic Arthritis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I1F-MC-RHCG: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2J-OX-JZLC: EMBER-3: A Phase 3, Randomized, Open-label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with endocrine Therapy
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Macrostat (Shanghai) Clinical Research?
The 2026-10-09 snapshot links Macrostat (Shanghai) Clinical Research to 10 distinct CTIS trials. Recorded services include Statistical analysis, Biostatistics and programming. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Macrostat (Shanghai) Clinical Research?
The most frequently recorded therapeutic areas are Immunology, Rheumatology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Macrostat (Shanghai) Clinical Research conducted?
The linked trials record locations in 15 countries, including Spain, Italy, France, Germany, Netherlands. These are trial locations, not confirmed office locations or countries where Macrostat (Shanghai) Clinical Research delivered services.
What can this page tell me about Macrostat (Shanghai) Clinical Research's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Macrostat (Shanghai) Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Macrostat (Shanghai) Clinical Research Co. Ltd.